Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

639

Citations

26

References

2009

Year

Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef, Michael Crump, Christian Gisselbrecht, Anna Laurell, Fritz Offner, Andrew Strahs, Anna Berkenblit, Orysia Hanushevsky,

Journal of Clinical Oncology

Abstract

Temsirolimus 175 mg weekly for 3 weeks followed by 75 mg weekly significantly improved PFS and objective response rate compared with investigator's choice therapy in patients with relapsed or refractory MCL.

References

	Year	Citations

Page 1